Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
This study is looking into a new treatment called focal brachytherapy for men with early-stage, low-risk prostate cancer. Brachytherapy is a type of radiotherapy where a radiation source is placed very close to the cancer. This particular study is 'focal', meaning it aims to treat only the small part of the prostate where the cancer is found, rather than the whole gland. The main goal is to see if this focused treatment is safe and if it causes fewer side effects than traditional treatments, while still being effective. It's a 'Phase II' study, which means it builds on earlier research and aims to confirm the treatment's safety and how well it's tolerated in a larger group of patients.
At a glance
What is this study about?
This study is about a new way to treat prostate cancer that is caught very early and is considered 'low-risk'. For some men, prostate cancer can grow very slowly and may not need aggressive treatment that affects the whole prostate. Traditional treatments often involve surgery or radiotherapy to the entire prostate, which can sometimes lead to side effects like problems with urinating or sexual function.
This study, called "Focal Brachytherapy in Patients With Selected 'Low-risk' Prostate Cancer," is looking at a treatment called HDR-Brachytherapy. 'HDR' stands for High Dose Rate, which is a specific way of delivering radiation. The key difference here is the word 'focal'. This means the treatment is highly targeted, aiming to deliver radiation only to the small part of the prostate where the cancer is found, leaving the healthy parts untouched as much as possible.
The main idea is to see if this focused approach can effectively treat the cancer while reducing the chances of side effects. It's a 'Phase II' clinical trial, which means researchers are carefully checking if this treatment is safe and well-tolerated by patients, and how effective it is for low-risk prostate cancer. The hope is that this targeted treatment could offer a better quality of life for men with suitable prostate cancer.
Key takeaways
- It's a study for men with early, low-risk prostate cancer.
- The treatment is a targeted radiotherapy called focal brachytherapy.
- Aims to treat only the cancer, sparing healthy prostate tissue.
- Hopes to reduce common side effects of prostate cancer treatment.
- Involves two short treatment sessions with long-term follow-up.
Who may be eligible?
To be considered for this study, you would need to be a man over 18 years old and have prostate cancer that has been confirmed by a doctor. Your cancer must be at an early stage and considered 'low-risk' – this means it's not spread outside the prostate and is slow-growing. Importantly, the cancer should only be in one small area of your prostate, and a special biopsy would be needed to confirm this.
There are also some specific medical requirements, such as your PSA (Prostate-Specific Antigen) level being 10 or less, and your prostate not being too large. Doctors would also need to check that you are generally well enough, with no other serious health issues like problems with blood clotting, and that you are expected to live for at least another 10 years. You would also need to be able to give your informed consent, meaning you understand the study and agree to take part.
However, this study would not be suitable if your cancer has already spread, or if it's considered more advanced (T2b or higher). If you have certain medical conditions that would make general anaesthesia or a similar anaesthetic risky, or if you have a bleeding disorder, you wouldn't be able to join. Your doctors would carefully review all these points with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you a man aged 18 or over?
- Has your doctor confirmed you have prostate cancer?
- Is your prostate cancer early-stage and low-risk?
- Is your cancer only in a small, single area of your prostate?
- Have you been told your PSA level is 10 or less?
- Are you generally in good health with a life expectancy of at least 10 years?
What does participation involve?
If you decide to take part in this study, the main treatment involves something called HDR-Brachytherapy. This is a type of radiotherapy where a radioactive source is temporarily placed inside your prostate, directly at the site of the cancer. You would receive two treatment sessions, each delivering a specific dose of radiation. These treatments are usually given under anaesthesia.
Before treatment, you'd have several checks, including a special 3D biopsy of your prostate to map the cancer precisely. Following your treatments, the research team would closely monitor your health and recovery. This would involve regular follow-up appointments and tests to check how well the treatment has worked and to look for any side effects. The exact number and timing of these appointments would be explained to you, but typically, clinical trials involve monitoring over several years to understand the long-term effects.
Potential risks and benefits
Locations (1)
- University HospitalVerified postcodeErlangen, Germany· Recruiting
Common questions
What is 'focal' brachytherapy?
It's a special type of radiotherapy that aims to treat only the small area where prostate cancer is found, instead of the whole prostate.
What does 'low-risk' prostate cancer mean?
It means the cancer is slow-growing, contained within the prostate, and hasn't spread, making it suitable for less aggressive treatments.
Will I need surgery if I join this study?
No, this study is testing radiotherapy (brachytherapy) as a different treatment option, not surgery.
Is this a new treatment?
Brachytherapy has been around for a while, but this study focuses on a specific, very targeted use of it for low-risk prostate cancer.
How long will I be involved in the study?
You will have two treatment sessions, and then regular check-ups over several years to monitor your progress and health.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.